Marcia Kean has been involved in the transformative side of biomedicine for 30+ years, working closely with scientific pioneers in biopharma, academe and government. She has led Feinstein Kean’s presence in the life sciences since the firm’s inception 25 years ago, including her tenure from 2002 to 2011 as the CEO, during which the firm tripled in size.

In the first two decades of the biotech industry, she partnered with dozens of CEOs of start-up firms to build value for their companies by shaping their visibility and credibility.

Soon after the Mapping of the Human Genome, Marcia established the nation’s first Molecular Medicine communications practice. She was among an early-adopter group seeking to introduce molecular medicine to the world, while she played a key role in the establishment and development of the Personalized Medicine Coalition. She has led Feinstein Kean’s presence in this field, serving on government panels and collaborating with scientists at Harvard, Duke, UCSF and elsewhere to define and overcome obstacles to adoption. She is also deeply embedded in the field of cancer informatics: she served as the co-Vice Chair of the Advisory Committee of the Institute of Medicine’s Cancer Informatics Workshop held in February 2012; served as the lead author of the Discussion Paper about a new coalition in the cancer community, used to frame the workshop; and presented the coalition concept at the event.

Under Marcia’s leadership, Feinstein Kean is proud to be co-hosting a Cancer Policy Conference in 2012, jointly with the Personalized Medicine Coalition and the American Association for Cancer Research.